Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hepatitis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage (...) to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot
Role of circulatory microRNAs in the pathogenesis of hepatitis C virus 29291226 2018 11 13 2347-3584 28 4 2017 Dec Virusdisease Virusdisease Role of circulatory microRNAs in the pathogenesis of hepatitis C virus. 360-367 10.1007/s13337-017-0407-3 Hepatitis C virus (HCV) is associated with one of the major health problem in world that ultimate results in the liver cirrhosis and leads to carcinoma of hepatocellular components round the world. More than 185 million people were found to be infected (...) with HCV. MicroRNAs are small oligonucleotide RNA having 18-22 nucleotides. Circulating mi-RNAs regulate the replication of HCV and HCV-induced liver fibrosis and HCC. By comparing the expression profiles of mi-RNAs of normal individuals with HCV infected patients, aberrant changes in expression of different mi-RNAs have been observed so it can be predicted that these mi-RNAs are associated with and play a central role in the hepatitis C infection and diseases associated with it. This review
Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Background: Vaccination, screening, and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection. However, recommendations vary among organizations, and their implementation has been suboptimal. The American College of Physicians' High Value Care Task Force and the Centers for Disease Control (...) and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care. Methods: A narrative literature review of clinical guidelines, systematic reviews, randomized trials, and intervention studies on hepatitis B vaccination, screening, and linkage to care published between January 2005 and June 2017 was conducted. Best Practice Advice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (including pregnant
Newly discovered hepatitis C virus minicores circulate in human blood Newly Discovered Hepatitis C Virus Minicores Circulate in Human Blood Francis J. Eng, 1 Ahmed El-Shamy, 1 Erin H. Doyle, 1 Arielle Klepper, 1 A. Scott Muerhoff, 2 and Andrea D. Branch 1 Hepatitis C virus (HCV) is one of the most prevalent causes of chronic blood-borne infections worldwide. Despite devel- opments of highly effective treatments, most infected individuals are unaware of their infection. Approximately 75 (...) , referred to as “minicores,” have the C-terminal portion of the mature p21 nucleocapsid (core) protein but lack the N-terminus. The estimated sizes of two prominent minicore proteins, 70 and 91, suggest that they begin at amino acids 70 and 91, respectively. Of interest, mutations in positions 70 and 91 are associated with Abbreviations: apoB, apolipoprotein B; DIPE, diisopropyl ether; FBS, fetal bovine serum; HCV, hepatitis C virus; HS, human serum; LDS, lithium dodecyl sulfate; LMIC, low- and middle
Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease Osteopontin Deletion Drives Hematopoietic Stem Cell Mobilization to the Liver and Increases Hepatic Iron Contributing to Alcoholic Liver Disease Fernando Magdaleno, 1 Xiaodong Ge, 1,2 Holger Fey, 3 Yongke Lu, 2 Harriet Gaskell, 1 Chuck C. Blajszczak, 1 Costica Aloman, 3 M. Isabel Fiel, 4 and Natalia Nieto 1,2,5 The aim of this study was to investigate (...) the role of osteopontin (OPN) in hematopoietic stem cell (HPSC) mobilization to the liver and its contribution to alcoholic liver disease (ALD). We analyzed young (14-16 weeks) and old (>1.5 years) wild-type (WT) littermates and global Opn knockout (Opn 2/2 ) mice for HPSC mobilization to the liver. In addition, WT and Opn 2/2 mice were chronically fed the Lieber–DeCarli diet for 7 weeks. Bone marrow (BM), blood, spleen, and liver were analyzed
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update) Guideline GuidelineofPreventionandTreatmentforChronicHepatitisB (2015Update) Jinlin Hou* 1 , Guiqiang Wang 2 , Fusheng Wang 3 , Jun Cheng 4 , Hong Ren 5 , Hui Zhuang 6 , Jian Sun 1 , Lanjuan Li 7 , Jie Li 6 , Qinghua Meng 8 , Jingmin Zhao 9 , Zhongping Duan 10 , Jidong Jia 11 , Hong Tang 12 , Jifang Sheng 7 ,JiePeng 1 , Fengmin Lu 6 ,QingXie 13 ,LaiWei* 14 ; Chinese Society of Hepatology, Chinese Medical Association (...) ; Chinese Society of Infectious Diseases, Chinese Medical Association 1 Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2 Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China; 3 The Institute of Translational Hepatology, 302 Hospital of PLA, Peking University, Beijing, China; 4 Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; 5 Institute for Viral
Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virusâ€related cirrhosis Sofosbuvir Induced Steven Johnson Syndrome in a Patient With Hepatitis C Virus-Related Cirrhosis Nipun Verma , 1 Shreya Singh, 2 Gitesh Sawatkar, 3 and Virendra Singh 1 Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious (...) or discontinuing this drug in patients with such severe dermatologic manifestations. (Hepatology Communications 2018;2:16-20) Introduction S ofosbuvir is an imperative drug used for the treatment of hepatitis C virus infection (HCV). It is relatively safe with fewer adverse effects than other treatments. (1) In this paper, we report a rare and potentially serious, dermatologic, adverse effect followingtheuseofsofosbuvir. Case Summary A 35-year-old male presented with a 3-year history of easily becoming
Interaction between the patatinâ€like phospholipase domainâ€containing protein 3 genotype and coffee drinking and the risk for acute alcoholic hepatitis Interaction Between the Patatin-Like Phospholipase Domain-Containing Protein 3 Genotype and Coffee Drinking and the Risk for Acute Alcoholic Hepatitis Suthat Liangpunsakul, 1-3 James J. Beaudoin , 4 Vijay H. Shah , 5 Puneet Puri, 6 Arun J. Sanyal, 6 Patrick S. Kamath, 5 Spencer G. Lourens, 7 Qing Tang, 7 Barry P. Katz, 7 David W. Crabb, 1,3,8 (...) and Naga P. Chalasani 1 Only a subset of subjects with excessive alcohol consumption develops alcoholic liver disease (ALD). One of the major risk factors for ALD is the genetic variant of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene. Coffee is one of the most commonly consumed beverages, and coffee consumption has been associated with lower levels of serum alanine aminotransferase. The aim of this study was to investigate the role of coffee drinking and PNPLA3 rs738409
Hairy and enhancer of split 6 prevents hepatic lipid accumulation through inhibition of Pparg2 expression Hairy and Enhancer of Split 6 Prevents Hepatic Lipid Accumulation Through Inhibition of Pparg2 Expression Jung Eun Park, Mikang Lee, Seong-Chul Kim, Yanqiao Zhang, James P. Hardwick, and Yoon Kwang Lee Peroxisome proliferator-activated receptor gamma (PPARc) is a master regulator for white adipocyte differentiation and lipid storage. The increased level of hepatic PPARc2 isoform reprograms (...) liver for lipid storage and causes abnormal fat accumulation in certain pathophysiologic conditions. The current study aimed to investigate a role of transcriptional repressor hairy and enhancer of split 6 (HES6) in the regulation of Pparg2 expression and hepatic steatosis induced by diet. Liver-speci?c overexpression of Hes6 using adenovirus reduced Pparg2 messenger RNA levels by 90% and hepatic tri- glyceride accumulation by 22% compared to the levels in mice injected with an adenoviral empty
A global perspective on hepatitis Bâ€related single nucleotide polymorphisms and evolution during human migration 29404438 2018 11 13 2471-254X 1 10 2017 12 Hepatology communications Hepatol Commun A global perspective on hepatitis B-related single nucleotide polymorphisms and evolution during human migration. 1005-1013 10.1002/hep4.1113 Genome-wide association studies have indicated that human leukocyte antigen (HLA)-DP and HLA-DQ play roles in persistent hepatitis B virus (HBV) infection (...) in Asia. To understand the evolution of HBV-related single nucleotide polymorphisms (SNPs) and to correlate these SNPs with chronic HBV infection among different populations, we conducted a global perspective study on hepatitis-related SNPs. We selected 12 HBV-related SNPs on the HLA locus and two HBV and three hepatitis C virus immune-related SNPs for analysis. Five nasopharyngeal carcinoma-related SNPs served as controls. All SNP data worldwide from 26 populations were downloaded from 1,000 genomes
HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations 29404439 2018 11 13 2471-254X 1 10 2017 12 Hepatology communications Hepatol Commun HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. 1014-1023 10.1002/hep4.1118 Hepatitis B virus (HBV) reactivation (HBVr) in recipients of allogeneic hematopoetic stem cells (aHSCs) appears heterogeneously (...) with respect to its frequency, manifestation, and outcome. The aim of this study was to present data from a large German cohort of recipients of aHSC transplantation (aHSCT), focusing on the incidence of HBVr in antibody to hepatitis B core antigen (anti-HBc)-positive aHSCT recipients, its clinical outcome, and the role of mutations in HBV. Between 2005 and 2015, 1,871 patients received aHSCT at University Hospital Essen. A follow-up of at least 6 months after transplant was available in 55 patients who
Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure 28928275 2017 09 20 2017 10 03 1468-3288 2017 Sep 19 Gut Gut Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. gutjnl-2017-314641 10.1136/gutjnl-2017-314641 The definition of acute-on-chronic liver failure (ACLF) based on cirrhosis, irrespective of aetiology, remains controversial. This study aimed to clarify (...) the clinicopathological characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) in a prospective study and develop new diagnostic criteria and a prognostic score for such patients. The clinical data from 1322 hospitalised patients with acute decompensation of cirrhosis or severe liver injury due to chronic hepatitis B (CHB) at 13 liver centres in China were used to develop new diagnostic and prognostic criteria. Of the patients assessed using the Chronic Liver Failure Consortium criteria
Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA499) NICE GUIDANCE ISSUED DECEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 1917 – October 2017 Glecaprevir/pibrentasvir (Maviret ® ) 100 mg/40 mg film-coated tablets Submission by AbbVie Ltd Additional note(s): ? AWMSG recommend that glecaprevir (...) /pibrentasvir (Maviret ® ) is used in accordance with the All Wales hepatitis C roll out programme. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3007), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available
Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection 29238510 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. 5646-5656 10.19082/5646 Hepatitis C infection is one of the main causes of chronic liver disorders worldwide. Nearly three percent (3%) of the world population has an HCV infection. Prevalence of HCV infection was higher in some groups (...) such as injected drug users (IDUs) and HIV positive populations. Acute hepatitis has proven asymptomatic in most cases, and delay of diagnosis might lead to late onset of hepatocellular carcinoma and cirrhosis. Some host characteristics such as age, gender, body mass index, and viral properties are associated with HCV outcome hepatitis. Although disease progression is typically slow, some risk factors such as alcohol abuse and coinfection of patients with HBV and HIV can worsen the disease. On the other hand
Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma 29104762 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. e000238 10.1136/esmoopen-2017-000238 Doxorubicin Transdrug (DT), a nanoformulation of doxorubicin, was demonstrated to overcome the chemoresistance of hepatocellular carcinoma (HCC) in (...) preclinical models. Its efficacy and safety were thus investigated in phase I and randomised phase II trials in unresectable HCC. Phase I was a single dose of DT through the hepatic intra-arterial (HIA) route, dose-escalating 3+3 trial, evaluating five-dose levels from 10 to 40 mg/m 2 with maximal tolerated dose (MTD) as primary endpoint. The multicentre phase II trial randomly assigned (2:1 ratio) patients to receive either 30 mg/m 2 of DT through HIA route every 4 weeks for up to three courses or best
Tardus parvus waveforms in Doppler ultrasonography for hepatic artery stenosis after liver transplantation: can a new cut-off value guide the next step? 29063132 2018 11 13 2366-0058 43 7 2018 Jul Abdominal radiology (New York) Abdom Radiol (NY) Tardus parvus waveforms in Doppler ultrasonography for hepatic artery stenosis after liver transplantation: can a new cut-off value guide the next step? 1634-1641 10.1007/s00261-017-1358-2 Considering the high false-positive diagnosis of the tardus (...) parvus waveform (TPW) in Doppler ultrasonography (DUS) for hepatic artery stenosis (HAS) after liver transplantation (LT), this study aimed to determine clinical features and new cut-off values to help guide treatment. This retrospective study was approved by an Institutional Review Board. A total of 171 LT recipients were included and underwent DUS and either computed tomography angiography or digital subtraction angiography with an interval < 4 weeks at least 1 month post-LT. The DUS of 69 patients
A qualitative study on individual experiences of chronic hepatitis B patients 29085657 2018 11 13 2054-1058 4 4 2017 10 Nursing open Nurs Open A qualitative study on individual experiences of chronic hepatitis B patients. 310-318 10.1002/nop2.100 The aim of this study was to explain the perception of patients with chronic hepatitis B regarding problems in the Iranian society. Descriptive qualitative research. In this qualitative study, 27 patients with chronic hepatitis B in Iran were selected (...) Hepat. 2016 Jan;23 (1):5-14 26280668 Liver Int. 2014 Nov;34(10):1452-63 24750532 J Clin Nurs. 2015 Feb;24(3-4):428-38 24811299 BMC Res Notes. 2011 Mar 03;4:45 21371332 J Clin Nurs. 2010 Oct;19(19-20):2869-78 20846231 J Caring Sci. 2016 Mar 01;5(1):57-66 26989666 Lancet. 2012 Dec 15;380(9859):2095-128 23245604 Hepat Mon. 2014 Aug 17;14(8):e20540 25237372 J Adv Nurs. 2008 Jun;62(6):712-24 18503656 Hepat Mon. 2016 Apr 26;16(4):e35577 27257428 Nurs Res Pract. 2013;2013:702079 23401760 East Mediterr
Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs. The U.S. Department of Veterans Affairs (VA) is the nation's largest care provider for hepatitis C virus (HCV)-infected patients and is uniquely suited to inform national efforts to eliminate HCV. An extensive array of delivery of services, policy guidance, outreach efforts, and funding has broadened the reach and capacity of the VA to deliver direct-acting antiviral (DAA) HCV therapy, supported